科研成果详情

题名When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study
作者
发表日期2024-12-31
发表期刊HEMATOLOGY   影响因子和分区
语种英语
原始文献类型Article
关键词Plasma cell disorder Omicron COVID-19 China
其他关键词COVID-19
摘要ObjectivesThis study aims to assess the impact of the nationwide Omicron outbreak in December 2022 on Chinese patients with plasma cell disorders (PCD), focusing on the clinical characteristics of PCD patients with COVID-19 and the risk factors contributing to adverse clinical courses (severity and hospitalization) and outcomes. MethodsA multicenter retrospective study was performed from December 1, 2022, to January 19, 2023. The study population includes 404 PCD patients, divided into a COVID-19 group (n = 342) and an uninfected group (n = 62). ResultsThe frequency of COVID-19 infection was 84.7% (342/404), and 16.4% (56/342) were severe COVID-19. Among the 277 patients with complete follow-up, 2 deaths (0.7%) were reported, while 231 (83.4%) recovered from COVID-19. Age > 65 (P = 0.02) and prior anti-CD38 monoclonal antibody (mAb) treatment within six months (P = 0.03) were independent risk factors for severe infection. Additionally, previous chimeric antigen receptor T-cell (CAR-T) therapy within six months was correlated with a higher risk of hospitalization (P = 0.04) and prolonged recovery time (P = 0.03). No significant protective effect of vaccination on infection or severe infection was observed (P > 0.05). ConclusionsThe latest Omicron outbreak results in higher rates of severe infection and mortality in PCD patients compared with the general population in China, highlighting the need to protect this vulnerable population during the pandemic. Recent use of anti-CD38 mAb and CAR-T therapy are associated with poorer clinical courses and outcomes of PCD patients with COVID-19.
资助项目National Natural Science Foundation of China [82270205, 82173267]; Natural Science Foundation of Zhejiang Province [LQ21H160015]
出版者TAYLOR & FRANCIS LTD
ISSN1024-5332
EISSN1607-8454
卷号29期号:1
DOI10.1080/16078454.2024.2411741
页数9
WOS类目Hematology
WOS研究方向Hematology
WOS记录号WOS:001330471300001
收录类别SCIE ; PUBMED
URL查看原文
PubMed ID39373666
通讯作者地址[Cai, Zhen]Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China.
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/220600
专题附属第一医院
附属第一医院_血液内科
通讯作者Cai, Zhen
作者单位
1.Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hematol, Hangzhou, Peoples R China;
2.Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China;
3.First Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China;
4.Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China;
5.Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Hematol, Shanghai, Peoples R China;
6.Nanchang Univ, Affiliated Hosp 2, Dept Hematol, Nanchang, Peoples R China;
7.Wenzhou Med Univ, Affiliated Hosp 1, Dept Hematol, Wenzhou, Peoples R China;
8.Fujian Med Univ, Fujian Inst Hematol, Union Hosp, Fuzhou, Peoples R China;
9.Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
推荐引用方式
GB/T 7714
Jiang, Xincheng,Han, Xiaoyan,Jin, Fengyan,et al. When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study[J]. HEMATOLOGY,2024,29(1).
APA Jiang, Xincheng., Han, Xiaoyan., Jin, Fengyan., An, Gang., Hou, Jian., ... & Cai, Zhen. (2024). When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study. HEMATOLOGY, 29(1).
MLA Jiang, Xincheng,et al."When Chinese patients with plasma cell disorders encountered the nationwide Omicron outbreak (December 2022): a real-world multicenter and multiregional study".HEMATOLOGY 29.1(2024).

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Jiang, Xincheng]的文章
[Han, Xiaoyan]的文章
[Jin, Fengyan]的文章
百度学术
百度学术中相似的文章
[Jiang, Xincheng]的文章
[Han, Xiaoyan]的文章
[Jin, Fengyan]的文章
必应学术
必应学术中相似的文章
[Jiang, Xincheng]的文章
[Han, Xiaoyan]的文章
[Jin, Fengyan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。